[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 26700, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 60, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 6731433, "exercisedValue": 0, "unexercisedValue": 64735872}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 64, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 3069385, "exercisedValue": 0, "unexercisedValue": 1429055}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 55, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 60, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3402742, "exercisedValue": 0, "unexercisedValue": 9008793}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 56, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 3243134, "exercisedValue": 0, "unexercisedValue": 5928890}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mike  Zahigian", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 51, "title": "Executive VP of Research & Development and Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Justin G. Claeys", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan P. Graham", "age": 62, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 2440307, "exercisedValue": 0, "unexercisedValue": 2105468}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 324.53, "open": 326.27, "dayLow": 325.38, "dayHigh": 331.12, "regularMarketPreviousClose": 324.53, "regularMarketOpen": 326.27, "regularMarketDayLow": 325.38, "regularMarketDayHigh": 331.12, "dividendRate": 9.0, "dividendYield": 0.0274, "exDividendDate": 1723766400, "payoutRatio": 1.5103, "fiveYearAvgDividendYield": 2.96, "beta": 0.58, "trailingPE": 56.787563, "forwardPE": 16.015585, "volume": 1771092, "regularMarketVolume": 1771092, "averageVolume": 2177454, "averageVolume10days": 1609430, "averageDailyVolume10Day": 1609430, "bid": 328.73, "ask": 328.92, "bidSize": 100, "askSize": 100, "marketCap": 176673783808, "fiftyTwoWeekLow": 248.38, "fiftyTwoWeekHigh": 346.85, "priceToSalesTrailing12Months": 5.7113137, "fiftyDayAverage": 322.3338, "twoHundredDayAverage": 295.8089, "trailingAnnualDividendRate": 8.76, "trailingAnnualDividendYield": 0.026992884, "currency": "USD", "enterpriseValue": 230017843200, "profitMargins": 0.10118, "floatShares": 535846191, "sharesOutstanding": 537329024, "sharesShort": 9788625, "sharesShortPriorMonth": 8984675, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0182, "heldPercentInsiders": 0.0024899999, "heldPercentInstitutions": 0.81107, "shortRatio": 5.42, "shortPercentOfFloat": 0.0182, "bookValue": 11.029, "priceToBook": 29.812311, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.459, "netIncomeToCommon": 3129999872, "trailingEps": 5.79, "forwardEps": 20.53, "pegRatio": 3.01, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 7.436, "enterpriseToEbitda": 19.887, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AMGN", "underlyingSymbol": "AMGN", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "firstTradeDateEpochUtc": 424704600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9376b97e-b428-3231-ba0b-142b20481cb4", "gmtOffSetMilliseconds": -14400000, "currentPrice": 328.8, "targetHighPrice": 381.0, "targetLowPrice": 180.0, "targetMeanPrice": 328.5, "targetMedianPrice": 344.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 23, "totalCash": 9301000192, "totalCashPerShare": 17.31, "ebitda": 11566000128, "totalDebt": 62644998144, "quickRatio": 0.755, "currentRatio": 1.264, "totalRevenue": 30933999616, "debtToEquity": 1057.3, "revenuePerShare": 57.659, "returnOnAssets": 0.04479, "returnOnEquity": 0.49268, "freeCashflow": 3012000000, "operatingCashflow": 6446000128, "earningsGrowth": -0.463, "revenueGrowth": 0.201, "grossMargins": 0.63412, "ebitdaMargins": 0.37389, "operatingMargins": 0.22914, "financialCurrency": "USD", "trailingPegRatio": 2.404, "__fetch_time": "2024-08-26"}]